New malaria vaccine shows 77% efficacy in trial, becoming first to surpass WHO target

Researchers behind

Researchers behind a novel malaria vaccine have reported that it’s up to 77% effective against the disease, which claims over 400,000 lives a year, making it the first inoculation to meet the WHO’s target efficacy.

The results of second-phase trials of the vaccine, known as R21 / Matrix-M and developed by the University of Oxford in cooperation with biotech company Novavax, were published in Preprints with The Lancet earlier this week.

Continue reading